<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580303</url>
  </required_header>
  <id_info>
    <org_study_id>EN3835-224</org_study_id>
    <nct_id>NCT04580303</nct_id>
  </id_info>
  <brief_title>CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques</brief_title>
  <official_title>A Phase 2 Multicenter, Open-label, Randomized, Parallel-group, Multiple-dose Study to Assess the Effectiveness, Safety and Satisfaction With Collagenase Clostridium Histolyticum Grid Technique Injections of Buttock or Thigh Cellulite With Laxity in Adult Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the safety and efficacy of CCH for the treatment of&#xD;
      mild to moderate edematous fibrosclerotic panniculopathy (cellulite) in participants with&#xD;
      moderate to severe dermal laxity in buttocks and thighs with comparison between two (2)&#xD;
      different CCH injection techniques.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Actual">September 24, 2021</completion_date>
  <primary_completion_date type="Actual">August 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of 1-level responders (+1 or better score) on the I-GAIS for either buttock or either thigh</measure>
    <time_frame>Day 180</time_frame>
    <description>Investigator-Global Aesthetic Improvement Scale (I-GAIS) is a 7-level scale ranging from &quot;+3&quot; (very much improved) to &quot;-3&quot; (very much worse) to determine the degree of improvement of the treated areas</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of 1-level responders (+1 or better score) on the I-GAIS for either buttock or either thigh</measure>
    <time_frame>Day 28, 56, 84, 112, and 140</time_frame>
    <description>Investigator-Global Aesthetic Improvement Scale (I-GAIS) is a 7-level scale ranging from &quot;+3&quot; (very much improved) to &quot;-3&quot; (very much worse) to determine the degree of improvement of the treated areas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>I-GAIS ratings</measure>
    <time_frame>Days 28, 56, 84, 112, 140, and 180</time_frame>
    <description>Investigator-Global Aesthetic Improvement Scale (I-GAIS) is a 7-level scale ranging from &quot;+3&quot; (very much improved) to &quot;-3&quot; (very much worse) to determine the degree of improvement of the treated areas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of I-level responders (+ 1 or better score) on the Subject Global Aesthetic Improvement Scale (S-GAIS) for either buttock or either thigh</measure>
    <time_frame>Day 28, 56, 84, 112, 140, and 180</time_frame>
    <description>The S-GAIS is a 7-level scale ranging from 3 (very much improved) to -3 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Body-Q Appraisal of the individual item cellulite scores and total score</measure>
    <time_frame>Change from baseline to Day 180</time_frame>
    <description>Body-Q Appraisal of Cellulite is a subset of questions from the Body-Q questionnaire that was developed to measure patient perceptions of weight loss and/or body contouring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to each study visit in Hexsel CSS Subsection D severity score</measure>
    <time_frame>Day 28 through Day 180</time_frame>
    <description>Hexsel CSS is a photonumeric scale that looks at 5 key morphologic features of cellulite using a 4-point scale from a low of O to a high of 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-AUX-I and Anti-AUX-II antibody levels</measure>
    <time_frame>Day 1 and 180</time_frame>
    <description>Anti- Clostridial class I collagenase (AUX-I) and Anti- Clostridial class II collagenase (AUX-II) antibody levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibodies to AUX-I and AUX-II</measure>
    <time_frame>Day 1 and 180</time_frame>
    <description>Neutralizing antibodies to AUX-I and AUX-II</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Edematous Fibrosclerotic Panniculopathy</condition>
  <condition>Cellulite</condition>
  <condition>Laxity; Skin</condition>
  <arm_group>
    <arm_group_label>Uniform 0.1-mL 1-Aliqout GRID Injection Technique</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uniform 0.3-mL 2-Aliquot GRID Injection Technique</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EN3835</intervention_name>
    <description>collagenase clostridium histolyticum (CCH)</description>
    <arm_group_label>Uniform 0.1-mL 1-Aliqout GRID Injection Technique</arm_group_label>
    <arm_group_label>Uniform 0.3-mL 2-Aliquot GRID Injection Technique</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have a BMI of 18 to &lt; 29.9 kg/m2.&#xD;
&#xD;
          2. Have either both buttocks or both posterolateral thighs with:&#xD;
&#xD;
               1. A score of 2 or 3 (mild or moderate cellulite) as reported by the investigator&#xD;
                  using the CR-PCSS, and&#xD;
&#xD;
               2. a Hexsel CSS Subsection D &quot;Grade of Laxity, Flaccidity, or Sagging Skin&quot; score of&#xD;
                  2 or 3 (moderate or severe) as determined by the investigator.&#xD;
&#xD;
          3. Have a negative pregnancy test or be of non-childbearing potential.&#xD;
&#xD;
          4. Be willing and able to cooperate with the requirements of the study.&#xD;
&#xD;
          5. Be willing to apply sunscreen to the treatment areas before each exposure to the sun&#xD;
             for the duration of the study (from the Screening Visit through the Day 180/Early&#xD;
             Termination Visit).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has a history of hypersensitivity or allergy to collagenase or any other excipients of&#xD;
             CCH.&#xD;
&#xD;
          2. At the Screening Visit has a CR-PCSS score of less than 2 or greater than 3 for the&#xD;
             area to be treated (buttocks or thighs) and/or has a Hexsel CSS Subsection D &quot;Grade of&#xD;
             Laxity, Flaccidity, or Sagging Skin&quot; score of less than 2 or greater than 3 (severe)&#xD;
             for the areas to be treated (buttocks or thighs).&#xD;
&#xD;
          3. Has a coagulation disorder which requires anticoagulant or antiplatelet medication&#xD;
             during the study (except for ≤ 150 mg aspirin daily), or has taken anticoagulant or&#xD;
             antiplatelet medication(s) within 14 days before injection of study treatment (except&#xD;
             for ≤ 150 mg aspirin daily).&#xD;
&#xD;
          4. Is a prisoner, an individual with impaired decision making capacity, employees&#xD;
             (temporary, part-time, full-time, etc) or a family member of the research staff&#xD;
             conducting the study, or of the sponsor, or of the contract research organization, or&#xD;
             of the Institutional Review Board (IRB)/Independent Ethics Committee (IEC), or in the&#xD;
             judgment of the investigator the subject is disadvantaged and vulnerable to coercion&#xD;
             due to lack of education, or due to poor economic circumstances.&#xD;
&#xD;
          5. Has received any collagenase treatments at any time prior to treatment in this study&#xD;
             and/or has received EN3835 or CCH in a previous investigational study for cellulite.&#xD;
&#xD;
          6. Is pregnant and/or is breast-feeding or plans to become pregnant and/or to breast-feed&#xD;
             during the course of the study.&#xD;
&#xD;
          7. Has a history of scarring due to keloids or abnormal wound healing.&#xD;
&#xD;
          8. Has local (in areas to be treated) conditions (thrombosis, vascular disorder, active&#xD;
             infection/inflammation, active cutaneous alteration, tattoo/mole) that restricts study&#xD;
             participation&#xD;
&#xD;
          9. Has history of drug or alcohol abuse within the 5 years prior to the Screening Visit.&#xD;
&#xD;
         10. Has evidence of clinically significant abnormalities, as judged by the investigator,&#xD;
             in any of the following: physical examination findings, electrocardiogram (ECG),&#xD;
             clinical laboratory values, or vital signs.&#xD;
&#xD;
             The sponsor's medical monitor will be required to review the results for confirmation&#xD;
             of eligibility in the case of any of the following: abnormalities in ECGs indicating&#xD;
             corrected QT interval (QTc) prolongation of 470 ms or greater; and clinical laboratory&#xD;
             values of liver enzymes&#xD;
&#xD;
         11. Has used or intends to use any of the local&#xD;
             application/therapies/injections/procedures that restricts study participation.&#xD;
&#xD;
         12. Has any other condition(s) that, in the investigator's opinion, might indicate the&#xD;
             participant to be unsuitable for the study.&#xD;
&#xD;
         13. For the subset of participants participating in the collection of ultrasound data, the&#xD;
             following exclusions will apply: participants will be excluded who have: a history of&#xD;
             a spinal laminectomy, a previous history or presence of vascular abnormalities (e.g.,&#xD;
             deep vein thrombosis, thrombophlebitis), a healing fracture, an impaired sensation&#xD;
             within, or near, the planned treatment area, or any implants within, or near, the&#xD;
             planned treatment area.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Chajko</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #3</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #2</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #1</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulite</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

